Resultado de AGM
PLC de Hikma Pharmaceuticals
Resultados de la Junta General de Accionistas 2024
LONDRES, 25 Abril 2024 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (the 'Empresa"O"Hikma') anuncia que su Asamblea General Anual ('AGM') was held at Sofitel London St James, 6 Waterloo Place, London SW1Y 4AN earlier today (25 April 2024) and commenced at 11.00 am. All the proposed resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 17 (inclusive) were passed as ordinary resolutions and Resolutions 18 to 21 (inclusive) were passed as special resolutions. Resolutions 22 to 25 (inclusive) were passed as ordinary resolutions on which only Independent Shareholders (that is, excluding members of the Darhold Concert Party, in accordance with the City Code on Takeovers and Mergers) were entitled to vote.
Copies of the resolutions dealing with special business passed at the AGM have been submitted to the FCA's Electronic Submission System and will be available from the National Storage Mechanism. Capitalised terms used but not otherwise defined in this announcement shall have the meanings given to them in the Notice of Meeting dated 22 March 2024.
The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the Notice of Meeting dated 22 March 2024) is set out below. The number of Ordinary Shares in issue at the close of business on 23 April 2024 was 234,718,492. At that time there were 12,833,233 Ordinary Shares held in treasury, which are not counted in the voting capital of the Company which, therefore, was 221,885,259.
Resolución | Votos a favor | % of Eligible Votes | Votos en contra | % of Eligible Votes | Total de votos emitidos | Votos totales emitidos como % de ISC1 | Retenido2 |
1. Para recibir el informe y las cuentas de 2023 | 181,198,032 | 99.77% | 420,652 | 0.23% | 181,618,684 | 81.85% | 2,002,379 |
2. Aprobar un dividendo complementario de 47 centavos por acción | 183,619,000 | 100.00% | - | 0.00% | 183,619,000 | 82.75% | 2,063 |
3. Reelegir a PricewaterhouseCoopers LLP como Auditor | 182,047,455 | 99.14% | 1,571,545 | 0.86% | 183,619,000 | 82.75% | 2,063 |
4. Autorizar al Comité de Auditoría para determinar la remuneración del Auditor | 183,350,922 | 99.85% | 268,755 | 0.15% | 183,619,677 | 82.75% | 1,386 |
5. To elect Riad Mishlawi as a Director | 182,679,147 | 99.49% | 931,142 | 0.51% | 183,610,289 | 82.75% | 10,774 |
6. Reelegir a Said Darwazah como Director | 175,159,173 | 95.46% | 8,330,791 | 4.54% | 183,489,964 | 82.70% | 131,099 |
7. Reelegir a Mazen Darwazah como Director | 173,570,357 | 94.59% | 9,919,072 | 5.41% | 183,489,429 | 82.70% | 131,634 |
8. To re-elect Victoria Hull as a Director | 171,362,071 | 93.33% | 12,252,259 | 6.67% | 183,614,330 | 82.75% | 6,733 |
9. Reelegir a Ali Al-Husry como Consejero | 181,637,139 | 98.99% | 1,851,670 | 1.01% | 183,488,809 | 82.70% | 132,254 |
10. Reelegir a John Castellani como Consejero | 182,829,533 | 99.57% | 783,105 | 0.43% | 183,612,638 | 82.75% | 8,425 |
11. Reelegir a Nina Henderson como Consejera | 182,724,512 | 99.52% | 889,994 | 0.48% | 183,614,506 | 82.75% | 6,557 |
12. Reelegir a Cynthia Flowers como Consejera | 182,948,600 | 99.64% | 665,730 | 0.36% | 183,614,330 | 82.75% | 6,733 |
13. Reelegir a Douglas Hurt como Director | 182,827,276 | 99.57% | 785,362 | 0.43% | 183,612,638 | 82.75% | 8,425 |
14. To re-elect Laura Balan as a Director | 183,048,421 | 99.69% | 565,909 | 0.31% | 183,614,330 | 82.75% | 6,733 |
15. To re-elect Dr Deneen Vojta as a Director | 183,188,326 | 99.77% | 426,004 | 0.23% | 183,614,330 | 82.75% | 6,733 |
16. Recibir y aprobar el informe anual sobre Remuneraciones | 167,893,145 | 91.44% | 15,724,640 | 8.56% | 183,617,785 | 82.75% | 3,278 |
17. Autorizar a los Directores para adjudicar acciones y otorgar derechos para suscribir acciones | 177,588,670 | 96.74% | 5,992,661 | 3.26% | 183,581,331 | 82.74% | 39,732 |
18. Para autorizar la supresión del derecho de suscripción preferente (General) | 175,982,388 | 95.86% | 7,602,205 | 4.14% | 183,584,593 | 82.74% | 36,470 |
19. Para autorizar la supresión del derecho de suscripción preferente (Adquisición o Inversión de Capital) | 168,246,123 | 91.85% | 14,920,062 | 8.15% | 183,166,185 | 82.55% | 454,878 |
20. Para autorizar a la Compañía a comprar Acciones Ordinarias | 182,110,127 | 99.32% | 1,251,967 | 0.68% | 183,362,094 | 82.64% | 258,969 |
21. Autorizar a la Sociedad para celebrar asambleas generales con no menos de 14 días naturales de antelación | 178,012,603 | 96.95% | 5,601,835 | 3.05% | 183,614,438 | 82.75% | 6,625 |
22. To approve the Rule 9 Waiver (Buyback Waiver) | 72,087,355 | 56.62% | 55,225,852 | 43.38% | 127,313,207 | 57.38%3 | 277,747 |
23. To approve the Rule 9 Waiver (Existing Awards Waiver) | 119,728,008 | 94.04% | 7,583,303 | 5.96% | 127,311,311 | 57.38%3 | 279,643 |
24. To approve the Rule 9 Waiver (2024 Awards Waiver) | 119,728,008 | 94.04% | 7,583,303 | 5.96% | 127,311,311 | 57.38%3 | 279,643 |
25. To approve the Rule 9 Waiver (2025 Awards Waiver) | 119,727,713 | 94.04% | 7,583,598 | 5.96% | 127,311,311 | 57.38%3 | 279,643 |
1 Issued Ordinary Share capital of the Company (excluding treasury shares).
2 A "withheld" vote is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
3 In order to comply with the City Code on Takeovers and Mergers, only the votes cast by the independent shareholders were counted for the purposes of Resolutions 22 to 25.
Declaración de dividendo final
The dividend of 47 cents per share will be paid on 3 May 2024 to shareholders on the register at the close of business on 22 March 2024. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.265373 a £1. El tipo de cambio del dinar jordano se fija con respecto al dólar estadounidense en alrededor de $ 1 a 0.708 JD.
Resolution 22 - approval of the Rule 9 Waiver (Buyback Waiver)
Resolution 22, being the ordinary resolution to approve the waiver of Rule 9 of the City Code on Takeovers and Mergers (the 'Rule 9 Waiver (Buyback Waiver)'), in connection with any increase in the Darhold Concert Party's holdings in the Company's voting capital to 30% or more, resulting from the exercise of the Company's share buyback authority pursuant to Resolution 20, was duly passed by 56.62% of the votes cast by the independent shareholders of the Company (being holders of Ordinary Shares other than the Darhold Concert Party) with 43.38% of the votes against. Resolution 22 enables Hikma to fully exercise the authority granted under Resolution 20 to make on-market purchases of up to approximately 10% of its issued Ordinary Share capital, which is a standing authority sought by the Company on an annual basis and at today's AGM was approved with a majority of 99.32%. Resolutions 20 and 22 together provide the Company with additional flexibility to return value to shareholders, including through a possible future buyback programme. Had Resolution 22 not been passed, the Company's optionality in this regard would have been restricted. Hikma will continue to engage with proxy advisers and shareholders on the rationale and merits of the Rule 9 Waiver (Buyback Waiver) as part of a constructive dialogue.
- TERMINA -
Consultas:
PLC de Hikma Pharmaceuticals | |
helen medianista Secretario de la empresa del grupo | +44 20 7399 2670 |
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.